{"id":"https://openalex.org/W3132740932","doi":"https://doi.org/10.1097/qai.0000000000002655","title":"Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study","display_name":"Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study","publication_year":2021,"publication_date":"2021-02-25","ids":{"openalex":"https://openalex.org/W3132740932","doi":"https://doi.org/10.1097/qai.0000000000002655","mag":"3132740932","pmid":"https://pubmed.ncbi.nlm.nih.gov/33587500","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8126488"},"language":"en","primary_location":{"id":"doi:10.1097/qai.0000000000002655","doi":"https://doi.org/10.1097/qai.0000000000002655","is_oa":true,"landing_page_url":"https://doi.org/10.1097/qai.0000000000002655","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1097/qai.0000000000002655","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019594570","display_name":"Jean Andre Van Wyk","orcid":"https://orcid.org/0000-0001-5719-7949","observed_orcids":["https://orcid.org/0000-0001-5719-7949"]},"institutions":[{"id":"https://openalex.org/I4210103149","display_name":"ViiV Healthcare (United Kingdom)","ror":"https://ror.org/01cc9yk21","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210103149"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Jean van Wyk","raw_affiliation_strings":["ViiV Healthcare, Brentford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Brentford, United Kingdom;","institution_ids":["https://openalex.org/I4210103149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070561857","display_name":"Mounir Ait\u2010Khaled","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103149","display_name":"ViiV Healthcare (United Kingdom)","ror":"https://ror.org/01cc9yk21","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210103149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mounir Ait-Khaled","raw_affiliation_strings":["ViiV Healthcare, Brentford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Brentford, United Kingdom;","institution_ids":["https://openalex.org/I4210103149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110241256","display_name":"Jes\u00fas Santos","orcid":"https://orcid.org/0000-0001-5196-8984","observed_orcids":["https://orcid.org/0000-0001-5196-8984"]},"institutions":[{"id":"https://openalex.org/I4210157481","display_name":"Hospital Cl\u00ednico Universitario Virgen de la Victoria","ror":"https://ror.org/05xxs2z38","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I158283456","https://openalex.org/I4210157481"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jesus Santos","raw_affiliation_strings":["Infectious Diseases Unit, Hospital Virgen de la Victoria, M\u00e1laga, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infectious Diseases Unit, Hospital Virgen de la Victoria, M\u00e1laga, Spain;","institution_ids":["https://openalex.org/I4210157481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078121291","display_name":"Stefan Scholten","orcid":"https://orcid.org/0000-0002-1863-8745","observed_orcids":["https://orcid.org/0000-0002-1863-8745"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefan Scholten","raw_affiliation_strings":["Praxis Hohenstaufenring, Cologne, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Praxis Hohenstaufenring, Cologne, Germany;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021328942","display_name":"Michael B. Wohlfeiler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1305519073","display_name":"AIDS Healthcare Foundation","ror":"https://ror.org/05n8mee18","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1305519073"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wohlfeiler","raw_affiliation_strings":["AIDS Healthcare Foundation, Miami Beach, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AIDS Healthcare Foundation, Miami Beach, FL;","institution_ids":["https://openalex.org/I1305519073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103864138","display_name":"Fa\u00efza Ajana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115387","display_name":"Centre Hospitalier de Tourcoing","ror":"https://ror.org/02carhc19","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210115387"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fa\u00efza Ajana","raw_affiliation_strings":["Infectious Diseases, Centre Hospitalier de Tourcoing, Tourcoing, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infectious Diseases, Centre Hospitalier de Tourcoing, Tourcoing, France;","institution_ids":["https://openalex.org/I4210115387"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102896295","display_name":"Bryn Jones","orcid":"https://orcid.org/0000-0001-9296-367X","observed_orcids":["https://orcid.org/0000-0001-9296-367X"]},"institutions":[{"id":"https://openalex.org/I4210103149","display_name":"ViiV Healthcare (United Kingdom)","ror":"https://ror.org/01cc9yk21","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210103149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Bryn Jones","raw_affiliation_strings":["ViiV Healthcare, Brentford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Brentford, United Kingdom;","institution_ids":["https://openalex.org/I4210103149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109467153","display_name":"Maria\u2010Claudia Nascimento","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103149","display_name":"ViiV Healthcare (United Kingdom)","ror":"https://ror.org/01cc9yk21","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210103149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Maria-Claudia Nascimento","raw_affiliation_strings":["ViiV Healthcare, Brentford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Brentford, United Kingdom;","institution_ids":["https://openalex.org/I4210103149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111549293","display_name":"Allan R. Tenorio","orcid":"https://orcid.org/0009-0007-2340-3389","observed_orcids":["https://orcid.org/0009-0007-2340-3389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allan R. Tenorio","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, NC;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018068497","display_name":"Don\u00a0E. Smith","orcid":"https://orcid.org/0000-0002-1308-4595","observed_orcids":["https://orcid.org/0000-0002-1308-4595"]},"institutions":[{"id":"https://openalex.org/I4210094512","display_name":"Albion Centre","ror":"https://ror.org/0066jxm83","country_code":"AU","type":"other","lineage":["https://openalex.org/I4210094512"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Don E. Smith","raw_affiliation_strings":["Albion Centre, Sydney, Australia; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Albion Centre, Sydney, Australia; and","institution_ids":["https://openalex.org/I4210094512"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103379830","display_name":"Jonathan Wright","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jonathan Wright","raw_affiliation_strings":["Statistics, GlaxoSmithKline, Stockley Park, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Statistics, GlaxoSmithKline, Stockley Park, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048242243","display_name":"Brian Wynne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Wynne","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, NC;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5019594570"],"corresponding_institution_ids":["https://openalex.org/I4210103149"],"apc_list":null,"apc_paid":null,"fwci":2.2115,"has_fulltext":true,"cited_by_count":33,"citation_normalized_percentile":{"value":0.90319082,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"87","issue":"2","first_page":"794","last_page":"800"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dolutegravir-lamivudine","display_name":"dolutegravir/lamivudine","score":0.9179999828338623},{"id":"https://openalex.org/keywords/tenofovir-alafenamide","display_name":"tenofovir alafenamide","score":0.9729999899864197},{"id":"https://openalex.org/keywords/antiretroviral-therapy-switching","display_name":"antiretroviral therapy switching","score":0.7310000061988831},{"id":"https://openalex.org/keywords/metabolic-health","display_name":"metabolic health","score":0.6159999966621399},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.843999981880188},{"id":"https://openalex.org/keywords/homa-ir","display_name":"HOMA-IR","score":0.9100000262260437},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.972000002861023},{"id":"https://openalex.org/keywords/lipid-profile","display_name":"lipid profile","score":0.7300000190734863},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.7329999804496765},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.7210000157356262},{"id":"https://openalex.org/keywords/virologically-suppressed","display_name":"virologically suppressed","score":0.6349999904632568},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.5879999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9055159091949463},{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.8824267387390137},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.7868512868881226},{"id":"https://openalex.org/C2911190787","wikidata":"https://www.wikidata.org/wiki/Q22075912","display_name":"Tenofovir alafenamide","level":5,"score":0.7270466089248657},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6437364220619202},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.6430874466896057},{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.6429921984672546},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6094601154327393},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.5033761858940125},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.4892399311065674},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4521586298942566},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.32145604491233826},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.2580927312374115},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.2529505789279938},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.20572179555892944},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.1727350354194641},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.15606442093849182},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.13987022638320923},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.0},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000099226","descriptor_name":"Dolutegravir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000409","descriptor_name":"Alanine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D008055","descriptor_name":"Lipids","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015430","descriptor_name":"Weight Gain","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/qai.0000000000002655","doi":"https://doi.org/10.1097/qai.0000000000002655","is_oa":true,"landing_page_url":"https://doi.org/10.1097/qai.0000000000002655","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8126488","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8126488/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8126488/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Acquir Immune Defic Syndr","raw_type":"Text"},{"id":"pmid:33587500","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33587500","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of acquired immune deficiency syndromes (1999)","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1097/qai.0000000000002655","doi":"https://doi.org/10.1097/qai.0000000000002655","is_oa":true,"landing_page_url":"https://doi.org/10.1097/qai.0000000000002655","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320312382","display_name":"ViiV Healthcare","ror":"https://ror.org/01cc9yk21"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3132740932.pdf","grobid_xml":"https://content.openalex.org/works/W3132740932.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1535373147","https://openalex.org/W1992258306","https://openalex.org/W2001878661","https://openalex.org/W2027002553","https://openalex.org/W2151050670","https://openalex.org/W2286675800","https://openalex.org/W2398957109","https://openalex.org/W2521293947","https://openalex.org/W2526154361","https://openalex.org/W2589922704","https://openalex.org/W2614048460","https://openalex.org/W2750840287","https://openalex.org/W2791127176","https://openalex.org/W2901041981","https://openalex.org/W2902620461","https://openalex.org/W2962964639","https://openalex.org/W2978347061","https://openalex.org/W2979917028","https://openalex.org/W2983909317","https://openalex.org/W3000709627","https://openalex.org/W3015440894","https://openalex.org/W3031539151","https://openalex.org/W3042726352","https://openalex.org/W3151441572","https://openalex.org/W3196483827","https://openalex.org/W6800962699"],"related_works":["https://openalex.org/W4384126965","https://openalex.org/W4207018194","https://openalex.org/W4309168458","https://openalex.org/W4392344369","https://openalex.org/W4311578047","https://openalex.org/W4393945392","https://openalex.org/W3199377640","https://openalex.org/W4402566499","https://openalex.org/W4408481577","https://openalex.org/W7214922767"],"abstract_inverted_index":{"BACKGROUND:":[0],"In":[1,78,90],"TANGO,":[2],"switching":[3,256,269],"to":[4,11,183,198,214,237,249,262],"dolutegravir/lamivudine":[5,123,171,239,263],"was":[6,164,226],"noninferior":[7],"at":[8,58,88,100,167,223],"48":[9,62,102,169,225],"weeks":[10],"continuing":[12],"3-/4-drug":[13,258],"tenofovir":[14,259],"alafenamide-based":[15,260],"regimens":[16,73,87,261],"in":[17,63,71,112,124,189,205,240,278],"virologically":[18],"suppressed":[19],"individuals":[20],"with":[21,28,122,170,234],"HIV-1.":[22],"Antiretroviral":[23],"agents":[24],"have":[25],"been":[26],"associated":[27],"weight":[29,95],"gain":[30],"and":[31,48,50,55,60,75,92,96,105,111,154,188,228],"metabolic":[32,56,221,265],"complications.":[33],"SETTING:":[34],"One":[35],"hundred":[36],"thirty-four":[37],"centers;":[38],"10":[39],"countries.":[40],"METHODS:":[41],"We":[42],"assessed":[43],"weight;":[44],"fasting":[45,97,125],"lipids,":[46],"glucose,":[47],"insulin;":[49],"prevalence":[51],"of":[52,83,161,220,274],"insulin":[53,155],"resistance":[54],"syndrome":[57,222],"baseline":[59,72,119],"week":[61,101,168,224],"TANGO":[64],"participant":[65],"subgroups":[66],"by":[67],"boosting":[68],"agent":[69],"use":[70],"(boosted":[74],"unboosted).":[76],"RESULTS:":[77],"each":[79],"treatment":[80,108,231],"group,":[81],"74%":[82],"participants":[84],"used":[85],"boosted":[86,91,114,191,271],"baseline.":[89],"unboosted":[93,207,242,280],"subgroups,":[94],"glucose":[98],"changes":[99],"were":[103,120],"small":[104],"similar":[106],"between":[107,230],"groups.":[109],"Overall":[110],"the":[113,190,206,241,279],"subgroup,":[115,281],"greater":[116],"decreases":[117],"from":[118,257,270],"observed":[121],"total":[126,141],"cholesterol":[127,133,144],"(P":[128,134,138],"<":[129,135,139],"0.001),":[130,136,140],"low-density":[131],"lipoprotein":[132,143],"triglycerides":[137],"cholesterol/high-density":[142],"ratio":[145,175],"(overall,":[146],"P":[147,151,157,185,200,216,251],"=":[148,152,158,186,201,217,252],"0.017;":[149],"boosted,":[150],"0.007),":[153],"(boosted,":[156],"0.005).":[159],"Prevalence":[160,219],"HOMA-IR":[162],"\u22652":[163],"significantly":[165],"lower":[166],"overall":[172],"[adjusted":[173],"odds":[174],"(aOR),":[176],"0.59;":[177],"95%":[178,195,211,246],"confidence":[179],"interval":[180],"(CI),":[181],"0.40":[182],"0.87;":[184],"0.008]":[187],"subgroup":[192,208,243],"[aOR,":[193,209,244],"0.56;":[194],"CI,":[196,212,247],"0.36":[197],"0.88;":[199],"0.012]":[202],"but":[203],"not":[204],"0.70;":[210],"0.31":[213],"1.58;":[215],"0.396].":[218],"low":[227],"consistent":[229],"groups":[232],"overall,":[233],"differences":[235],"trending":[236],"favor":[238],"0.41;":[245],"0.15":[248],"1.09;":[250],"0.075].":[253],"CONCLUSION:":[254],"Generally,":[255],"improved":[264],"parameters,":[266],"particularly":[267],"when":[268],"regimens.":[272],"Because":[273],"smaller":[275],"sample":[276],"size":[277],"results":[282],"warrant":[283],"further":[284],"investigation.":[285]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2021-03-01T00:00:00"}